CJC-1295 (no DAC) + Ipamorelin Blend Peptide

The CJC-1295/Ipamorelin combination produces synergistic GH release through dual receptor activation: CJC-1295 activates GHRH receptors (amplifying pulse amplitude by 2-3x) while Ipamorelin activates GHS-R1a ghrelin receptors (increasing pulse frequency). Combined, they achieve 3-5x baseline GH elevation — significantly more than either compound alone. Critically, this combination preserves the natural pulsatile GH pattern rather than creating continuous, non-physiological elevation.

The combination is considered the "gold standard" GH research stack because it is selective: unlike GHRP-6 (which increases cortisol, prolactin, and appetite) or Hexarelin (cortisol increase), the CJC-1295/Ipamorelin pair stimulates GH release without significant effects on other hormonal axes.

Comparative research quantifying the synergistic effect of the CJC/Ipamorelin combination:

• CJC-1295 alone: 2-3x baseline GH peak (GHRH-R amplitude effect)
• Ipamorelin alone: 2-3x baseline GH peak (GHS-R1a frequency effect)
• CJC-1295 + Ipamorelin combined: 5-8x baseline GH peak (synergistic: amplitude × frequency)

The synergy follows the pharmacological principle that agonists acting through different receptor systems on the same effector cell (somatotroph) produce multiplicative rather than additive responses. This is analogous to how beta-agonists + anticholinergics produce synergistic bronchodilation through different receptor pathways on the same airway smooth muscle cell.

Research comparing the CJC/Ipamorelin combination to single-agent GH secretagogue protocols reveals several advantages:

• vs GHRP-6 alone: No hunger increase, no cortisol spike, no prolactin elevation
• vs Hexarelin alone: No cortisol increase, no desensitization (Hexarelin loses efficacy after ~14 days; CJC/Ipa does not)
• vs MK-677 alone: More physiological pulsatile GH pattern (MK-677 produces continuous 24h elevation that may downregulate GH receptors)
• vs exogenous GH: Preserves hypothalamic-pituitary feedback, maintains pulsatility, no suppression of endogenous GH production

The lack of desensitization is particularly important — the blend can be used in long-term research protocols without the efficacy fade seen with GHRP-6 and especially Hexarelin.

One of the foundational studies establishing the rationale for combining a GHRH analog (such as CJC-1295 no DAC, a tetra-substituted GRF(1-29)) with a growth hormone secretagogue (such as Ipamorelin) was conducted by Bowers and colleagues, who demonstrated that the co-administration of GHRH with a GHRP produces growth hormone (GH) release that exceeds the simple additive sum of either peptide alone.

Study Design:

• Subjects: Healthy adult male and female volunteers
• Design: Crossover comparison of GHRH alone, GHRP alone, and GHRH + GHRP co-administration
• Endpoint: Serum GH AUC over 120 minutes post-administration

Key Findings:

• GHRH alone produced a ~10-fold increase over baseline GH
• GHRP alone produced a ~15-fold increase over baseline GH
• GHRH + GHRP co-administration produced a greater than additive response, with peak GH levels frequently exceeding the arithmetic sum of the two individual responses
• The synergistic effect was observed across age groups and was attributed to complementary mechanisms — GHRH amplifying somatotroph cAMP signaling while the GHRP simultaneously suppressed somatostatin tone and activated phospholipase C signaling

Research Context: This synergy is the mechanistic basis for combining CJC-1295 (no DAC) and Ipamorelin in a single research blend. Because Ipamorelin is the most selective GHS-R agonist studied — lacking measurable cortisol or prolactin elevation seen with GHRP-2 or GHRP-6 — the CJC-1295/Ipamorelin pairing has become a benchmark research model for clean, pulsatile GH-axis activation in preclinical studies.

Foundational preclinical work established that combining a GHRH analog with a growth hormone-releasing peptide (GHRP) produces supra-additive growth hormone release that neither compound achieves alone. Bowers and colleagues, in seminal work characterizing GHRP synergy with GHRH, demonstrated that the two classes of secretagogues act through distinct yet complementary pathways and that their combination produces a markedly amplified GH pulse rather than a simple summation of individual responses.

Key preclinical observations relevant to the CJC-1295 (no DAC) + Ipamorelin blend:

• Synergistic amplitude: Co-administration of a GHRH analog with a GHRP produces GH peaks 2- to 5-fold higher than the larger of the two single-agent responses in animal and early human studies.
• Somatostatin tone reduction: GHRPs (including Ipamorelin) functionally antagonize somatostatin at the somatotroph, removing the brake on GHRH-stimulated GH release.
• Pulsatility preservation: Unlike continuous GH or GHRH exposure, pulsatile co-secretagogue stimulation preserves the episodic GH secretion pattern that downstream IGF-1 signaling depends upon.
• Selectivity profile: Ipamorelin, unlike GHRP-2 and GHRP-6, did not elevate cortisol, prolactin, or ACTH in preclinical models, making the blend a cleaner research probe for isolating somatotropic effects.

These mechanistic findings provided the rationale for combining a short-acting GHRH analog (CJC-1295 without DAC, t½ ~30 min) with a selective GHS-R1a agonist (Ipamorelin, t½ ~2 h). The pairing is used in research to model square-wave versus pulsatile GH exposure and to dissect GHRH-dependent versus ghrelin-dependent contributions to somatotroph activation.

The selection of CJC-1295 without the Drug Affinity Complex (DAC) for blending with Ipamorelin is a deliberate pharmacokinetic choice studied in receptor pharmacology research. The non-DAC tetrasubstituted GHRH(1-29) analog (also called CJC-1295 no DAC, Mod GRF 1-29) carries four amino acid substitutions — D-Ala², Gln⁸, Ala¹⁵, and Leu²⁷ — that confer enzymatic stability against DPP-IV and trypsin-like proteolysis without extending the half-life into the multi-day range characteristic of the DAC-conjugated version.

Teichman and colleagues characterized the pharmacokinetics of CJC-1295 with DAC, showing a sustained half-life of ~6-8 days due to covalent albumin binding via the maleimidopropionic acid linker. This prolonged exposure produces a continuous, non-pulsatile elevation in GH and IGF-1 — useful for some research models, but incompatible with studying acute pulsatile co-secretagogue dynamics.

Key pharmacokinetic differences exploited in the no-DAC + Ipamorelin blend:

• CJC-1295 no DAC half-life: ~30 minutes — short enough to produce a discrete GH pulse rather than tonic stimulation.
• Ipamorelin half-life: ~2 hours — provides a complementary GHS-R1a stimulation window.
• Pulse architecture: The combination produces a single, well-defined GH pulse with peak at ~30-60 min and return to baseline within 3-4 hours, mirroring physiological nocturnal pulses.
• IGF-1 modeling: Pulsatile rather than continuous GH exposure permits study of intermittent JAK2/STAT5 activation and downstream hepatic IGF-1 transcription.

This pharmacokinetic profile makes the no-DAC blend the preferred tool in research that aims to model endogenous-pattern GH secretion, whereas DAC-modified analogs are used when sustained square-wave exposure is the experimental objective.